FDA Approves Supernus' Orenitram

The Food and Drug Administration approved the pulmonary arterial hypertension treatment Orenitram that Supernus Pharmaceuticals Inc. (Nasdaq: SUPN) developed with United Therapeutics Corp. (Nasdaq: UTHR). Shares of Supernus climbed 98 cents to close at $8.38 while United Therapeutics stock fell $1.66 to close at $112.85.


Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here